Syncona Limited Directorate Change

 
TIDMSYNC 
 
Syncona Limited 
 
                Legal Entity Identifier - 213800X8MBI5VQITLW60 
 
         Syncona appoints Robert Hutchinson as Non-Executive Director 
 
16 October 2017 
 
Syncona Ltd, a leading healthcare company focused on investing in and building 
global leaders in life science, today announces that Robert Hutchinson has been 
appointed as Non-Executive Director of the Company, with effect from 1 November 
2017. 
 
Mr Hutchinson brings many years of broad financial experience to the role, 
having spent 28 years at KPMG. He was appointed partner in 1999 and specialised 
in the audit of banking and fund clients.  He led the firm's fund and private 
equity practices for seven years and served as Head of Audit for KPMG in the 
Channel Islands for five years until 2013. 
 
Mr Hutchinson retired from practice in 2014 and is a Fellow of the Institute of 
Chartered Accountants in England and Wales. He served as President of the 
Guernsey Society of Chartered and Certified Accountants between 2007 and 2009. 
 
There is no information to be disclosed pursuant to LR 9.6.13R in respect of Mr 
Hutchinson.  As at the date of this announcement, he has no beneficial 
interests in the ordinary shares of the Company. 
 
[ENDS] 
 
Enquiries 
 
Syncona Ltd 
Siobhan Weaver 
Tel: [phone] 
 
Tulchan Communications 
Martin Robinson 
Lisa Jarrett-Kerr 
Tel: [phone] 
 
Notes to Editors 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. Our current investment 
portfolio consists of seven high quality companies in life science and a 
leading range of fund investments. 
 
We seek to partner with the best, brightest and most ambitious minds in science 
to build globally competitive businesses. We are established leaders in gene 
therapy, cell therapy and advanced diagnostics, and focus on delivering 
dramatic efficacy for patients in areas of high unmet need. 
 
Our market leading funds portfolio seeks to generate superior returns by 
investing in long only and alternative investment funds. This represents a 
productively deployed evergreen funding base which enables us to take a long 
term approach to investing in life sciences as we target the best new 
opportunities and support our existing portfolio companies to grow and succeed. 
 
Syncona is aligned with two of the premium charitable funders in UK science, 
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both 
of which are significant shareholders in our business.  We make a donation of 
0.3% of Net Asset Value to a range of charities each year. 
 
 
 
END 
 

(END) Dow Jones Newswires

October 16, 2017 05:39 ET (09:39 GMT)